Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL30426594 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2399952 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL1405692 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL155761 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL14672487 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19581677 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL4589 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL7607795 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL440873 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL15005742 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731184-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | Glenmark Pharmaceuticals Limited (IN) | 2026-04-29 | — | — | EP | claimed |
| WO-2026047392-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | GLENMARK SPECIALTY S.A. (CH) | 2026-03-05 | — | — | WO | claimed |
| US-12558314-B1 | Pressurized inhalation composition of tiotropium | GLENMARK SPECIALTY S.A. (CH) | 2026-02-24 | — | — | US | claimed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-4323049-B1 | UNDERARM SPRAY DELIVERY DEVICE | XERO PHARMACEUTICALS IP B V (NL) | 2025-05-28 | — | — | EP | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| EP-2104490-B2 | MICRONISED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION | CHIESI FARM SPA (IT) | 2024-06-26 | — | — | EP | claimed |
| EP-3982923-B1 | CONTINUOUS PROCESS FOR THE PREPARATION OF ANTICHOLINERGIC DRUGS | HOVIONE SCIENTIA LTD (IE) | 2024-05-15 | — | — | EP | claimed |
| EP-4066874-B1 | INHALERS | NORTON WATERFORD LTD (IE) | 2024-04-24 | — | — | EP | claimed |
| WO-2003084502-A1 | INHALATION KIT COMPRISUNG INHALABLE POWDER OF TIOTROPIUM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | claimed |
| US-20030181478-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-25 | — | — | US | claimed |
| US-20030171586-A1 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| US-6608055-B2 | Anhydrous crystalline tiotropium bromide | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-19 | — | — | US | claimed |
| US-20030087927-A1 | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-05-08 | — | — | US | claimed |
| US-20030069310-A1 | Salicylic acid salts of salmeterol | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-10 | — | — | US | claimed |
| US-20020169321-A1 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | claimed |
| US-20020137764-A1 | .0005-5 wt% of a tiotropium salt, an antiallergic, antihistamine, steroid, or leukotriene antagonist, water or water/ethanol mixture and a preservative; antiasthmatics and chronic obstructive pulmonary disease treatment | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-26 | — | — | US | claimed |
| US-20020111363-A1 | Antihistamines; atomizing | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | US | claimed |
| US-20020110529-A1 | For use in therapy of chronic obstructive pulmonary disease and asthma | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171586-A1 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | CHRNA9, THOP1, ADRB3 | CHRM3 5/4885CHRM2 41/4885CHRM1 83/4885 |
| US-12558314-B1 | Pressurized inhalation composition of tiotropium | ADRB2, ADRB1, CFTR | CHRM3 29/4885CHRM2 18/4885CHRM1 49/4885 |
| US-20020111363-A1 | Antihistamines; atomizing | HRH1, CHRM3, HRH4 | CHRM3 2/4885CHRM2 8/4885CHRM1 7/4885 |
| US-20020169321-A1 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | CHRNA9, THOP1, ADRB3 | CHRM3 5/4885CHRM2 41/4885CHRM1 83/4885 |
| US-20030069310-A1 | Salicylic acid salts of salmeterol | SQLE, SALL4, SUCLA2 | CHRM3 2709/4885CHRM2 3524/4885CHRM1 3319/4885 |
| US-20020137764-A1 | .0005-5 wt% of a tiotropium salt, an antiallergic, antihistamine, steroid, or leukotriene antagonist, water or water/ethanol mixture and a preservative; antiasthmatics and chronic obstructive pulmonary disease treatment | LTA4H, IL5, LTB4R | CHRM3 17/4885CHRM2 25/4885CHRM1 23/4885 |
| US-20020110529-A1 | For use in therapy of chronic obstructive pulmonary disease and asthma | IL5, CHRM3, CHRM5 | CHRM3 2/4885CHRM2 6/4885CHRM1 18/4885 |
| US-20030181478-A1 | A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide | LTA4H, LTB4R, LTB4R2 | CHRM3 22/4885CHRM2 25/4885CHRM1 27/4885 |
| US-20030087927-A1 | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | CHRNA9, CHRM2, CHRNA7 | CHRM3 4/4885CHRM2 2/4885CHRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.